vidarabine phosphate and Leukemia, Lymphocytic, Chronic, B-Cell

vidarabine phosphate has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 58 studies

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19905 (8.62)18.7374
1990's38 (65.52)18.2507
2000's14 (24.14)29.6817
2010's1 (1.72)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bénichou, J; Cazin, B; Delmer, A; Divine, M; Dreyfus, B; Dumontet, C; Eghbali, H; Feugier, P; Grosbois, B; Guibon, O; Jaubert, J; Leleu, X; Leporrier, M; Leprêtre, S; Mahé, B; Maloisel, F; Maloum, K; Tournilhac, O; Travade, P1
Dunleavy, K; Figg, WD; Grant, ND; Jaffe, ES; Janik, JE; Marti, GE; Steinberg, SM; Stetler-Stevenson, M; Tohnya, T; White, T; Wilson, WH1
Budman, DR; Cascella, P; D'Amico, P; Eisenberg, P; Etcubanas, E; Ferrer, JM; Hinderling, PH; Lichtman, SM; Melikian, A; Musgrave, K; O'Mara, V; Williams, GJ; Zervos, G1
Berthou, C; Bron, D; de Boeck, K; Deconinck, E; Foussard, C; Guibon, O; Johnson, SA; Kramer, MH; Lister, TA; Littlewood, TJ; Marcus, RE; Montillo, M; Rossi, JF; Tollerfield, SM; van Hoof, A1
Castro, JE; Eldering, E; Evers, LM; Grummels, A; Hooijbrink, B; Kater, AP; Kipps, TJ; Kramer, MH; Mackus, WJ; van Lier, RA; van Oers, MH1
Bosanquet, AG; Daniel, PT; Dörken, B; Hummel, M; Sturm, I1
Catovsky, D; Dearden, C; Kochethu, G; MacConkey, C; Matutes, E; Milligan, DW1
Cabanillas, F; Dimopoulos, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Kemena, A; O'Brien, S; Plunkett, W; Robertson, LE1
Charan, N; Crowley, JJ; Knight, L1
Rodriguez, G1
Appelbaum, FR; Chapman, RA; Elias, L; Godwin, JE; Grever, MR; Head, DR; Metz, EN; Stock-Novack, D; Weick, JK1
Keating, MJ; Robertson, LE1
Binet, JL1
Gerrits, WB; Haak, HL; Wijermans, PW1
Abassi, ZA; Carter, A; Green, J; Nakhoul, F1
Astrow, AB1
Angelopoulou, MA; Boussiotis, VA; Kontopidou, F; Pangalis, GA; Poziopoulos, C1
Jacobs, P; Pillay, GS; Wood, L1
Begleiter, A; Liliemark, JO; Plunkett, W; Reed, JC1
Keating, MJ; McLaughlin, P; Robertson, LE1
Cheson, BD; Chun, HG; Fallavollita, A; Sorensen, JM; Vena, DA1
Faber, E; Heczko, M; Hubácek, J; Indrák, K; Jarosová, M; Papajík, T; Pikalová, Z; Raida, L; Slezák, P; Sulovská, I1
Alcaraz, L; Bay, JO; Béal, D; Chollet, P; Cure, H; Fouassier, M; Plagne, R; Travade, P1
Andreeff, M; Brown, W; Consoli, U; DiRaimondo, F; El-Tounsi, I; Kleine, HD; Plunkett, W; Robinson, JR; Sandoval, A; Snell, V1
Filangeri, M; Morabito, F; Oliva, B; Sculli, G1
Barbui, T; Coiffier, B; Foran, JM; Hiddemann, W; Johnson, SA; Lister, TA; Norton, AJ; Radford, JA; Rohatiner, AZ; Tollerfield, SM; Wilson, MP1
Abdulkadyrov, KM; Beresneva, IA; Gershanovich, ML; Medvedeva, NV; Samuskevich, IG; Zaritskiĭ, AIu1
Arima, N; Mizoguchi, H; Ohno, R; Shirakawa, S; Takatsuki, K; Tomonaga, M1
Cullen, MH; de Takats, PG; Foran, JM; Johnson, SA; Klein, M; Kraus, C; Lister, TA; Orchard, J; Oscier, D; Tighe, M1
Hodohara, K; Imamura, M; Kobayashi, S; Miyawaki, S; Mizoguchi, H; Ohnishi, K; Ohno, R; Tango, T; Tomonaga, M1
Clauvel, J; Coppo, P; Ferchal, F; Lassoued, K; Scieux, C1
Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S1
Brown, KR; Chen, S; Choi, BY; Lin, ZY; Skalski, V1
Buckingham, L; Petersen, KS; Plate, JM; Schofield, CM; Shahidi, H1
Autrand, C; Binet, JL; Boudjerra, N; Cazin, B; Chastang, C; Chevret, S; Desablens, B; Dighiero, G; Divine, M; Dreyfus, B; Feugier, P; Jaubert, J; Leporrier, M; Maloum, K; Rapp, MJ; Travade, P1
Binet, JL; Boogaerts, MA; Bosch, F; Catovsky, D; Feremans, W; Klein, M; Kovacs, M; Marcus, R; Montillo, M; Van Hoof, A; Verhoef, G; Zinzani, PL1
Culligan, D; Cunningham, D; Gieschen, H; Johnson, S; Klein, M; Orchard, JA; Oscier, D; Parker, A1
Kontoyiannis, DP; Samonis, G1
Nightingale, SL2
Schilling, PJ; Vadhan-Raj, S1
Adams, JD; Chun, HG; Kummet, TD; List, AF1
Cheson, BD1
Balcerzak, S; Grever, M; Kraut, E; Leiby, J; Malspeis, L; Metz, E; Neidhart, J1
Keating, MJ1
Cervantes, F; Montserrat, E; Rozman, C; Salgado, C1
Childs, CC; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; McCredie, KB; O'Brien, S; Schachner, J; Talpaz, M1
Bastion, Y; Bryon, PA; Coiffier, B; Espinouse, D; Tigaud, JD1
Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS1
Ahmed, T; Arlin, ZA; Arnold, PM; Budman, DR; Coleman, M; Feldman, EJ; Lichtman, SM; Mittelman, A; Puccio, CA; Silver, RT1
Büchner, T; Essink, M; Freund, M; Hiddemann, W; Ottensmeier, C; Rottmann, R; Thiel, A; van de Loo, J; Wörmann, B1
Bauman, J; Fernandez, M; Keating, M; Kemena, A; Plunkett, W1
Balcerzak, SP; Coltman, CA; Files, JC; Greenberg, BR; Grever, MR; Hutton, JJ; Kopecky, KJ; Talley, R; Von Hoff, DD1
Kantarjian, H; Keating, MJ; McCredie, KB; Redman, J; Talpaz, M1
Barlogie, B; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; McCredie, KB; Plunkett, W; Redman, J; Talpaz, M; Velasquez, W1
Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W1

Reviews

9 review(s) available for vidarabine phosphate and Leukemia, Lymphocytic, Chronic, B-Cell

ArticleYear
Fludarabine phosphate: a new active agent in hematologic malignancies.
    Seminars in hematology, 1994, Volume: 31, Issue:1

    Topics: Animals; Clinical Trials as Topic; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1994
Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
    Investigational new drugs, 1994, Volume: 12, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Vidarabine Phosphate

1994
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
    Cancer treatment and research, 1993, Volume: 64

    Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Rate; Vidarabine Phosphate

1993
Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Nouvelle revue francaise d'hematologie, 1993, Volume: 35, Issue:1

    Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1993
Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
    European journal of haematology, 1996, Volume: 56, Issue:4

    Topics: Acute Kidney Injury; Allopurinol; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Middle Aged; Sodium Bicarbonate; Tumor Lysis Syndrome; Vidarabine Phosphate

1996
Why do drugs work in CLL?
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine Phosphate

1996
Fludarabine phosphate in lymphoma: an important new therapeutic agent.
    Cancer treatment and research, 1996, Volume: 85

    Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1996
Infectious complications of purine analog therapy.
    Current opinion in infectious diseases, 2001, Volume: 14, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cladribine; Humans; Immune Tolerance; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine Phosphate

2001
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Remission Induction; Vidarabine Phosphate

1990

Trials

20 trial(s) available for vidarabine phosphate and Leukemia, Lymphocytic, Chronic, B-Cell

ArticleYear
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.
    British journal of haematology, 2008, Volume: 143, Issue:1

    Topics: Adult; Aged; Biomarkers; Creatinine; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine Phosphate

2008
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Middle Aged; Staurosporine; Treatment Outcome; Vidarabine Phosphate

2011
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Safety; Survival Rate; Treatment Outcome; Vidarabine Phosphate

2004
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia.
    British journal of haematology, 2006, Volume: 133, Issue:2

    Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Transplantation Conditioning; Vidarabine Phosphate

2006
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.
    Leukemia, 1993, Volume: 7, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine Phosphate

1993
Fludarabine in chronic leukaemia.
    Lancet (London, England), 1996, May-25, Volume: 347, Issue:9013

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Vidarabine Phosphate

1996
Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
    Leukemia & lymphoma, 1996, Volume: 21, Issue:3-4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine Phosphate

1996
Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2

    Topics: Adult; Antimetabolites, Antineoplastic; Clinical Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; National Institutes of Health (U.S.); Survival Analysis; Treatment Outcome; United States; Vidarabine Phosphate

1997
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1999
[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
    Voprosy onkologii, 1998, Volume: 44, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate

1998
[Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine Phosphate

1999
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Vidarabine Phosphate

1999
[Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1999, Volume: 40, Issue:12

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate

1999
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
    Blood, 2001, Oct-15, Volume: 98, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Hospitalization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Phosphoramide Mustards; Prednisone; Prognosis; Proportional Hazards Models; Sample Size; Survival Rate; Time Factors; Vidarabine Phosphate; Vincristine

2001
Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-15, Volume: 19, Issue:22

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate

2001
The bioavailability of oral fludarabine phosphate is unaffected by food.
    The hematology journal : the official journal of the European Haematology Association, 2001, Volume: 2, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate

2001
A comprehensive phase I and II clinical investigation of fludarabine phosphate.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Vidarabine Phosphate

1990
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Survival Rate; Vidarabine Phosphate

1991
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
    British journal of cancer, 1991, Volume: 64, Issue:1

    Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate

1991
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine Phosphate

1991

Other Studies

29 other study(ies) available for vidarabine phosphate and Leukemia, Lymphocytic, Chronic, B-Cell

ArticleYear
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
    Cancer investigation, 2002, Volume: 20, Issue:7-8

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Vidarabine Phosphate

2002
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.
    Leukemia, 2005, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine Phosphate

2005
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.
    BMC cancer, 2005, Aug-18, Volume: 5

    Topics: Aged; Antineoplastic Agents; Apoptosis; Arginine; Chlorambucil; Codon; Cyclophosphamide; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, p53; Homozygote; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Polymorphism, Single-Stranded Conformational; Prognosis; Proline; Vidarabine Phosphate; Vincristine

2005
Lysis pneumonopathy associated with the use of fludarabine phosphate.
    The Western journal of medicine, 1994, Volume: 161, Issue:6

    Topics: Adult; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Respiratory Insufficiency; Tumor Lysis Syndrome; Vidarabine Phosphate

1994
Severe immunodeficiency in patients treated with fludarabine monophosphate.
    European journal of haematology, 1993, Volume: 50, Issue:5

    Topics: Adult; Aged; Bone Marrow; Female; Humans; Immunoglobulins; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; T-Lymphocyte Subsets; Vidarabine Phosphate

1993
Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:8

    Topics: Antimetabolites, Antineoplastic; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Salvage Therapy; South Africa; Vidarabine Phosphate

1996
[Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy].
    Vnitrni lekarstvi, 1997, Volume: 43, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Vidarabine Phosphate

1997
Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia.
    Hematology and cell therapy, 1997, Volume: 39, Issue:4

    Topics: Aged; Autoimmune Diseases; Drug Administration Schedule; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thrombocytopenia; Vidarabine Phosphate

1997
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
    Blood, 1998, Mar-01, Volume: 91, Issue:5

    Topics: Antigens, CD19; Antimetabolites, Antineoplastic; Apoptosis; B-Lymphocytes; CD3 Complex; CD4 Antigens; CD8 Antigens; Cell Cycle; Cyclosporine; Flow Cytometry; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes; Tumor Cells, Cultured; Vidarabine Phosphate

1998
More on purine analog-induced apoptosis in B cell chronic lymphocytic leukemia.
    Leukemia, 1998, Volume: 12, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine Phosphate

1998
Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate.
    Annals of hematology, 2000, Volume: 79, Issue:1

    Topics: Antimetabolites, Antineoplastic; Astroviridae Infections; Feces; Gastroenteritis; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mamastrovirus; Microscopy, Electron; Middle Aged; Vidarabine Phosphate

2000
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Leukemia, 2000, Volume: 14, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine

2000
A 3'-5' exonuclease in human leukemia cells: implications for resistance to 1-beta -D-arabinofuranosylcytosine and 9-beta -D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate.
    The Journal of biological chemistry, 2000, Aug-18, Volume: 275, Issue:33

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Cell Nucleus; Cells, Cultured; Cytidine Monophosphate; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Exodeoxyribonuclease V; Exodeoxyribonucleases; Exonucleases; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphocytes; Magnesium; Neoplasm Proteins; Potassium Chloride; Protein Biosynthesis; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation; Vidarabine Phosphate

2000
Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis.
    Experimental hematology, 2000, Volume: 28, Issue:11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Transformation, Viral; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine Phosphate

2000
From the Food and Drug Administration.
    JAMA, 1990, Feb-09, Volume: 263, Issue:6

    Topics: Arabinonucleotides; Blepharospasm; Botulinum Toxins; Drug Industry; Eyelid Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Orphan Drug Production; Strabismus; Tampons, Surgical; Vidarabine Phosphate

1990
Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
    The New England journal of medicine, 1990, Sep-20, Volume: 323, Issue:12

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Cytomegalovirus Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine Phosphate

1990
Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
    The American journal of medicine, 1990, Volume: 89, Issue:3

    Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Metastasis; Male; Tumor Lysis Syndrome; Vidarabine Phosphate

1990
Fludarabine phosphate--looking forward.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate

1990
Fludarabine phosphate: an effective therapy for lymphoid malignancies.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate

1990
Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
    Lancet (London, England), 1990, Nov-03, Volume: 336, Issue:8723

    Topics: Adult; Antimetabolites, Antineoplastic; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Pulmonary Fibrosis; Risk Factors; Vidarabine Phosphate

1990
Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:5

    Topics: Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine Phosphate

1991
From the Food and Drug Administration.
    JAMA, 1991, Jul-10, Volume: 266, Issue:2

    Topics: Antimetabolites, Antineoplastic; Drug Labeling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sepsis; Tablets; Transfusion Reaction; United States; United States Food and Drug Administration; Vidarabine Phosphate; Yersinia enterocolitica; Yersinia Infections

1991
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
    Annals of hematology, 1991, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine Phosphate

1991
A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
    Clinica chimica acta; international journal of clinical chemistry, 1991, Aug-30, Volume: 200, Issue:2-3

    Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Therapy; Fluorescent Dyes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Sensitivity and Specificity; Vidarabine Phosphate

1991
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
    Nouvelle revue francaise d'hematologie, 1988, Volume: 30, Issue:5-6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Bone Marrow; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Remission Induction; Vidarabine Phosphate

1988
Fludarabine therapy in chronic lymphocytic leukemia (CLL).
    Nouvelle revue francaise d'hematologie, 1988, Volume: 30, Issue:5-6

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Texas; Vidarabine Phosphate

1988
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
    Blood, 1989, Volume: 74, Issue:1

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Prognosis; Thrombocytopenia; Vidarabine Phosphate

1989
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Blood, 1989, Nov-01, Volume: 74, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine Phosphate

1989
Fludarabine shows promise for some leukemia patients.
    Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:3

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine; Vidarabine Phosphate

1989